Background: Current guidelines and practices for thyroid function testing are strongly affected by the usually higher patient billing charges and Medicare reimbursement for thyrotropin (TSH) vs free thyroxine (FT 4 ) tests, despite their comparable direct costs.
ties for detecting clinical hyperthyroidism and hypothyroidism. The TSH test detects subclinical function, and it monitors thyroxine treatment better; the FT 4 test detects central hypothyroidism, and it monitors rapidly changing function better. Direct costs for both were equal, but charges for the TSH test were higher. The average direct cost per patient, starting with the FT 4 test, was $4.61; starting with the TSH test, $5.90; and starting with both tests together, $6.50. Medicare reimbursements correlated poorly with costs.
Conclusions:
Starting with the TSH test and reflexing to the FT 4 test provides a better first-line all-purpose sequence than the reverse. In managed care settings, the slightly higher direct cost of this approach is offset by greater clinical effectiveness. In fee-for-service settings, cost differences can be nearly eliminated by equalizing TSH and FT 4 charges to reflect current direct-cost realities. Obtaining both tests together overcomes the disadvantages of each at a slightly higher direct cost. Med. 1998; 158:266-272 P ROFESSIONAL societies have issued different guidelines for thyroid function testing, [1] [2] [3] [4] [5] [6] and complex variations are advised depending on the clinical settings and the characteristics of individual patients. [2] [3] [4] 7, 8 Much of the controversy involves the trade-off between quality and cost, 3, [8] [9] [10] [11] with cost information derived from older technology. Recent laboratory improvements have reduced and equalized the direct costs of these tests, suggesting the need to reconsider their use in routine clinical practice.
Arch Intern
Our search was for an optimal testing strategy applicable to nearly all patients in both managed care and fee-for-service settings.Determiningeffectivenessfromreviewing the literature and obtaining current direct costs from 4 laboratories that provide testing for 85% of Hawaii's population, we comparedalternativestrategies:startingwith the thyrotropin (TSH) test, followed, if the TSH level was abnormal, by the free thyroxine(FT 4 )immunoassay;startingwiththeFT 4 test, followed, if that result was abnormal, bytheTSHtest;anddoingbothteststogether.
results of 500 consecutive patients at each laboratory by test combinations into normal, hyperthyroid, hypothyroid, subclinical hyperthyroid, subclinical hypothyroid, and "other"( Table 2) . Table 3 displays the average distribution of results for all 2000 patients and identifies the contents of the "other" category.
COST ANALYSIS
Direct costs (reagents and personnel) per reportable test for TSH and FT 4 at Tripler, Straub, and DLS were similar (Table 4) , ie, between $3.06 and $3.61. Costs at Kaiser were higher ($6.81), consistent with higher batch frequency (3/d) and smaller batch sizes. The average costs of the TSH and FT 4 tests were identical ($4.15). The average cost of the FT 4 test was lower than that of the FT 4 index ($4.15 vs $6.92) because the FT 4 index required both the total thyroxine level and the triiodothyronine uptake. Reagent costs per test in the United States by companies that provided more than 5% of all reagents averaged $1.10 for the FT 4 (range, $0.35-$2.29) and $1.92 for the TSH (range, $0.45-$2.79). 16 These national reagent costs are less than ours, but are not directly comparable because we counted each reportable result as an individual test, and IMS America, Ltd (a health care and marketing research company in Plymouth Meeting, Pa), counted each step to achieve a reportable result as a test, whether standard, duplicate, repeat, or quality control.
COST OF ALTERNATIVE TEST SEQUENCES FT 4 Test Followed, If the Results Are Abnormal, by TSH Test (Kaiser Approach)
Applying this protocol to all 2000 patients resulted in an average of 88.8% of patients being classified as euthyroid; 3.2%, hyperthyroid; 3.2%, hypothyroid; and 4.8%, other (Table 3 ). The subclinical categories (11.1%) were subsumed within the normal group. Direct laboratory costs include FT 4 tests on all patients and TSH assays on an additional 11.2%, or a total of $4.61 per patient ( Table 5) . 
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LABORATORY METHODS
Kaiser used the semiautomated Baxter (now Dade International, Deerfield, Ill) Stratus II fluorometric assay for all tests. 12 Tripler and DLS used the Boehringer Mannheim Corporation (Indianapolis, Ind) ES 300 enzyme-linked immunosorbent assay for all tests. 13 Straub used the Becton Dickinson Immunodiagnostics (now ICN Pharmaceuticals, Diagnostic Division, Orangeburg, NY) Simultrac solid-phase system for simultaneous TSH and FT 4 tests, 14, 15 Nuclear Medical Laboratories-Organon Teknika Corporation (Durham, NC) radioimmunoassay kits for total thyroxine level and triiodothyronine uptake, and Diagnostic Products Corporation (Los Angeles, Calif) radioimmunoassay kits for total triiodothyronine level. None of the laboratories measured FT 4 levels by equilibrium dialysis. Although the immunoassay methods may not be as accurate as the equilibrium dialysis method, they are nevertheless the tests routinely used by all laboratories in the study, which includes 85% of tests done in Hawaii.
For each laboratory, the assays performed well within the manufacturers' precision specifications. Each laboratory participated successfully in the College of American Pathologists' Ligand Assay Series proficiency testing program.
COST ANALYSIS OF LABORATORY TESTS
Direct costs of reagents and personnel per reportable test result were calculated for each of the 4 laboratories. Reagent costs were based on the manufacturer's list price uncorrected for volume discounts.
Kaiser costs are excluded-as it had special problems with multiple daily runs-the average direct cost of doing both tests concurrently at Straub, Tripler, and DLS was $6.50 (Table 5) .
Independent Physician TestOrdering Practices (DLS Approach)
Test ordering by the independent physician clientele of DLS ( December 1993 December , 1994 , and 1995 indicate a shift to more effective combinations, with a substantial increase in orders for the TSH test and decreases for the thyroxine assay and the FT 4 index. Improvement was accomplished by actively educating physicians, adjusting patient billing charges for the TSH test equal to those for the FT 4 test, starting routinely with the TSH test and then doing the FT 4 test for the largest private hospital in the study that was the major client of DLS, restricting FT 4 tests and the FT 4 index in the same specimen, and providing pathologist consultation if the TSH and FT 4 test were not the primary tests ordered.
From the viewpoint of individual physicians and patients, equalizing the charges nearly eliminates the influence of cost as a basis of choice between tests. From the socioeconomic perspective, 17 starting with the TSH test may still cost more because the detection of subclinical function categories by the TSH test leads to more secondary testing.
MEDICARE REIMBURSEMENTS
Substantial discrepancies were found between Medicare reimbursements and direct costs of laboratory tests ( Table   Table 3 Table 3 ).
5). Reimbursements for individual tests in December 1993
ranged from $9.95 for the total thyroxine test to $24.12 for the TSH test (Table 6 ), a difference of 142%, whereas the direct costs ranged from $3.52 to $4.15 (Table 4) , a difference of 18%. Reimbursement for the TSH test was $24.12 and for the FT 4 test, $13.06 (Table 6 ), a difference of 85%, whereas there was no difference in direct costs. Medicare reimbursed laboratories for each test when charges for the FT 4 and the FT 4 index were submitted together.
COMMENT
Clinicians order thyroid function tests to detect functional abnormalities in patients with possible, suspected, or known thyroid disease. The ideal test or combination of tests is sensitive and specific for hyperthyroidism and hypothyroidism, independent of thyroidbinding protein changes, not falsely altered by thyroxine treatment, and relatively inexpensive. The tests most often used are the FT 4 index, FT 4 , and TSH. Arguments are presented for applying dual testing 1, 18 or for sequencing them by starting with 1 test and following it, if the results are abnormal, with a second test. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Guidelines often suggest variations, depending on the reasons for testing, such as screening, case finding, or monitoring in the contexts of stable or rapidly changing function. It is generally conceded that the TSH assay is the best test overall, but much of the controversy involves the tradeoff between quality and cost 3, [8] [9] [10] [11] because charges for the TSH test are routinely higher than for the FT 4 .
FT 4 ASSAY vs FT 4 INDEX
Whether used as the primary or secondary test, either the FT 4 test or the FT 4 index is often needed to confirm diagnoses, classify subclinical functional states, monitor thyroxine treatment with the objective of suppressing TSH, observe the course of rapidly changing thyroid function, and detect and observe instances of pituitary or hypothalamic dysfunction. To choose between them, we considered diagnostic accuracy and cost. The sensitivities of the FT 4 assay and the FT 4 index for detecting clinical hyperthyroidism and hypothyroidism are similar. 18 In our study, the FT 4 index had a higher direct cost per 
ADVANTAGES OF STARTING WITH THE FT 4 TEST
Several studies of cost-effectiveness have concluded that the thyroxine-based tests are preferable to the TSH test as the first test in a sequence. 3, 4, 7, 10, 19 It is argued that subclinical hyperthyroidism and hypothyroidism, detected only by the TSH test, are not harmful and that tests that do not detect them are sufficient to identify patients who will benefit from treatment. 29, 30 Triiodothyronine toxicosis will be missed, but many disorders are identifiable clinically. The rare but important cases of central hypothyroidism are detectable by the FT 4 test but not by the TSH test. 31 The sometimes confusing miscellaneous categories that occur when starting with the TSH test 32 are reduced. The diagnostic accuracy of the FT 4 assay is better than the TSH when the thyroid function status is rapidly changing, especially after the recent treatment of hyperthyroidism. 33, 34 The strongest argument for choosing the FT 4 as the routine first test is its lower cost because charges for the FT 4 are consistently lower than for the TSH.
ADVANTAGES OF STARTING WITH THE TSH TEST
The introduction of second-generation ("sensitive") TSH tests brought a reconsideration of testing strategies. 25, 27, 28, 35 They accurately identify both hyperthyroidism and hypothyroidism, are not falsely affected by protein-binding variations or thyroxine treatment, and are important, if not critical, for monitoring replacement and suppressive therapy with thyroxine. 36, 37 Excluding special situations as noted earlier, a TSH test result within normal limits best defines euthyroidism. 6, 18, 35 The TSH is the only test capable of detecting subclinical hypothyroidism and hyperthyroidism. If these conditions are important and common, there is further reason to start with this test. Data are accumulating that sustained subclinical hypothyroidism results in subtle signs and symptoms, [38] [39] [40] cardiac abnormalities, 38, 40 and disturbed lipid metabolism, [41] [42] [43] all relieved by treatment. Together with positive results on antithyroid antibody tests, it predicts the delayed onset of overt hypothyroidism. 44, 45 Treatment may 22 or may not 46 increase the health-related quality of life. Sustained subclinical hyperthyroidism (determined by undetectable secondgeneration TSH test results and a normal FT 4 level) has been reported to result in correctable clinical signs and symptoms, 47 abnormalities of the heart, [47] [48] [49] and an increased risk of osteoporosis. [50] [51] [52] [53] [54] Although the consequences of these subclinical states are under investigation, it seems reasonable to avoid these conditions whenever possible. Truly subclinical hyperthyroidism can be most accurately determined by third-and fourthgeneration TSH tests with a normal FT 4 level by equilibrium dialysis. These more accurate tests are not widely available, however, and are likely to be more costly.
The prevalence of subclinical categories in our study of 2000 consecutive patients who had any thyroid test ordered averaged 11.1% of all patients. Others have obtained similar or higher results, depending on the practice settings.
The 5.1% "other" category we found (Table 3 ) may be confusing. Most of these had a low but detectable TSH level (between 0.1 and 0.5 µIU/L). Many such results occur in patients being treated with thyroxine; in these, the TSH information alone is usually sufficient. In patients who have no clinical indications of thyroid disease, low but detectable levels rarely indicate or predict the presence of hyperthyroidism. 55, 56 Without clinical evidence of thyroid dysfunction, these groups usually need no further testing.
The argument most effectively raised against routinely starting with the TSH test is that current charges for it are higher than for the FT 4 . 7, 11, 22 Using a variety of methods in our 4 laboratories, we found only minor direct cost differences, and the national survey 16 confirms the small differences in reagent costs. 
ADVANTAGES OF DOING THE TSH AND FT 4 TESTS TOGETHER
A single first test with high sensitivity and specificity is appropriate for most purposes. Although our choice is the TSH test, obtaining TSH and FT 4 test results together circumvents the limitations of either test used separately. The arguments for combining the tests are strongest for patients at risk for thyroid dysfunction before treatment is started; for those with changing thyroid function, as frequently occurs in the months following the treatment of hyperthyroidism; for those with nonthyroidal illnesses (euthyroid sick syndrome); for those taking drugs known to affect the test results; and for those with possible or known central hypothyroidism. 31 Both test results are available immediately without further decisions by the physician or laboratory. They provide reassuring confirmation of euthyroidism and often new information in patients more likely to have thyroid dysfunction. 1, 18, 32 In our study, the direct cost of this approach was $6.50 per patient compared with $5.09 for starting with the TSH test and $4.61 starting with the FT 4 assay. We have not analyzed it, but the direct cost may not be substantially greater than a strategy of waiting for results from the first test, producing a subset of abnormal samples, running the second test separately, and collating reports.
CONCLUSION
New cost information suggests a reconsideration of routine thyroid function testing strategies. Because direct costs between widely used sensitive TSH and FT 4 tests do not differ substantially, recommendations for sequencing these tests can be based more clearly on professional judgment. This applies both to managed care settings and to fee-for-service settings willing to equalize charges of the TSH and FT 4 tests to reflect equal costs.
For routine testing, we currently favor a protocol that starts with the TSH test, followed by an FT 4 assay if the TSH test result is abnormal. This strategy is applicable to nearly all routine screening, diagnostic testing, and treatment monitoring. Major cautions are in patients with rapidly changing thyroid function and those suspected of having or known to have central hypothyroidism. It optimizes diagnostic accuracy, reduces laboratory work, and simplifies ordering by clinicians. The small additional cost of starting with the TSH test compared with starting with the FT 4 assay is outweighed by the added value of detecting the subclinical function states and by more effective thyroxine therapy monitoring. Obtaining these tests together, especially in patients at higher risk for thyroid dysfunction, increases efficiency and diagnostic accuracy at a slightly greater cost, but individual requirements should be accommodated. June 5, 1997. This 
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